BIOCON PHARMA LIMITED

Sign up for our Newsletter.

Biocon and Zentiva receive DCP approval for Liraglutide in EU, for generic Victoza to treat Type-2 Diabetes and Saxenda for weight management.

Optimising R&D budgets for pharma companies involves balancing efficiency with innovation through portfolio management, adaptive trials, focusing on high-value therapeutic areas, data-driven decision making, collaborations, cost-efficient operations, agile budgeting, early regulatory engagement, and enhancing talent utilisation. Advanced technologies like AI, systems biology, and real-world evidence can transform R&D, while partnerships and digitalisation improve efficiency. Rising research costs, complex drug systems, and stringent regulations pose challenges, but strategic portfolio management, mergers, acquisitions, and embracing technical innovations offer solutions.

Kiran Mazumdar-Shaw, founder of Biocon, is India’s richest self-made woman with a net worth of Rs 28,835 crore. She donated Rs 63 crore to the University of Glasgow and focuses on affordable cancer care through her philanthropic initiatives. Recognized globally, she ranks 82nd on Forbes World’s 100 Most Powerful Women list.

Nifty traders faced volatility on December 13, with a sharp recovery from early losses. The Nifty surged nearly 600 points from its lows, reviving hopes for higher levels. Key resistance is at 24,857, with potential to reach 25,000. The upcoming week's focus is on the US Federal Reserve's policy decision, expected to influence market direction.

Reliance Industries acquired a 74% stake in Navi Mumbai IIA for ₹1,628 crore. Biocon's biosimilar YESINTEK received EMA approval. Aurobindo Pharma's biosimilar Zefylti got a positive EMA opinion. Bharat Forge invested €2.5 million in Edgelab S.p.A. Lupin acquired three anti-diabetes trademarks from Boehringer Ingelheim. Aeroflex Industries plans to raise ₹400 crore via QIP. Afcons Infrastructure secured a ₹1,007 crore metro rail contract. HBL Power Systems received a ₹1,522.4 crore order for Train Collision Avoidance Systems. RITES won a ₹297.67 crore project for an Integrated Check Post. 63 Moons Technologies approved a ₹1,950 crore settlement by NSEL Investors Forum.

Biocon's Kiran Mazumdar-Shaw hails Toregem Biopharma's drug, which regrows human teeth by blocking USAG-1 protein, potentially replacing dental implants. Tested successfully on mice, clinical trials began in October at Kyoto University Hospital. Aimed initially at congenital tooth loss, researchers hope to launch the drug by 2030.

On Dec 1, 2024, Biocon announced FDA approval of YESINTEK™ (ustekinumab-kfce), a biosimilar to J&J’s STELARA®, for Crohn’s disease, Ulcerative Colitis, Plaque Psoriasis, and Psoriatic Arthritis. Biocon has a settlement and licensing agreement with Janssen to commercialize YESINTEK in the U.S. by Feb 22, 2025.